Schrodinger, Inc. (SDGR) CEO Ramy Farid on Q4 2021 Results - Earnings Call Transcript

Schrodinger, Inc. (NASDAQ:SDGR) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET

Company Participants

Ramy Farid - CEO, President & Director
Jaren Madden - SVP, IR & Corporate Communications
Joel Lebowitz - CFO & EVP
Karen Akinsanya - EVP, Chief Biomedical Scientist and Head, Discovery R&D

Conference Call Participants

Do Kim - Piper Sandler
Vikram Purohit - Morgan Stanley
Andrew Tsai - Jefferies
Lucas Baranowski - Craig-Hallum Capital
Gary Nachman - BMO Capital Markets
Derik De Bruin - Bank of America Merrill Lynch
Gaurav Goparaju - Berenberg

Operator

Thank you for standing by. Welcome to Schrodinger's Conference Call for the Fourth Quarter and Full Year 2021 Financial Results. My name is Charlie, and I'll be your operator for today's call. [Operator Instructions]. Please be advised that this call is being recorded at the company's request.

Now I would like to introduce your host for today's conference call Ms. Jaren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Jaren Madden

Thank you and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our fourth quarter and full year 2021 financial results. Earlier today we issued a press release summarizing our financial results and progress across the company which is available on our website at schrodinger.com.

Here with me on our call today are Ramy Farid, Chief Executive Officer; Joel Lebowitz, Chief Financial Officer; and Karen Akinsanya, President of R&D Therapeutics. Following our prepared remarks, we'll open the call for Q&A. I'd like to remind you that during today's call, management will make statements related to our business that are forward looking and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our future financial performance, including our outlook for the full year 2022